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Abstract 
 
Aims To evaluate in a general population, the effect of dysglycaemia, insulin resistance and metabolic 
parameters, on heart rate (HR), HR recovery and HR variability (HRV). 
Methods 447 participants in the D.E.S.I.R. study were classified according to glycaemic status over the 
preceding nine years All were free of cardiac antecedents and were not taking drugs which alter HR. 
During five consecutive periods: rest, deep-breathing, recovery, rest and lying-to-standing, HR and HRV 
were evaluated and compared by ANCOVA and trend tests across glycaemic classes. Spearman correlation 
coefficients quantified the relations between cardio-metabolic risk factors, HR and HRV. 
Results HR differed between glycaemic groups, except during deep-breathing. Between rest and deep-
breathing periods, diabetic patients had a lower increase in HR than others (Ptrend<0.01); between deep-
breathing and recovery, the HR of diabetic patients continued to increase, for others, HR decreased 
(P<0.009). HR was correlated with capillary glucose and triglycerides during the five test periods. HRV 
(SDRR) differed according to glycaemic status, especially during the recovery period. In contrast to HR, 
HRV was negatively correlated with age. After age, sex and BMI adjustment, HRV was correlated with 
triglycerides at two test periods. Change in HR between recovery and deep-breathing was negatively 
correlated with HRV at rest, (r=-0.113,P<0.05): lower resting HRV was associated with HR acceleration.  
Conclusions HR, but not HRV, was associated with glycaemic status and capillary glucose. After deep-
breathing, HR recovery was altered in known diabetic patients, and was associated with reduced HRV. 
Over-weight was a major correlate of HRV. 
 
 
Keywords: diabetes, epidemiology, heart rate, heart rate variability, heart rate recovery 
12/01/2011 Article 1 3/23 
Introduction 
Elevated heart rate (HR) predicts cardiovascular morbidity and mortality in both diabetic [1,2] and non-
diabetic individuals [3,4]. HR is the result of fitness, neurohormonal factors and the autonomic nervous 
system function. In type 2 diabetic patients, HR is faster [5] and this may be related to cardiac 
autonomic neuropathy (CAN). Fasting plasma glucose is associated with higher resting HR [6] and in the 
Insulin Resistance Atherosclerosis Study, HR was associated with insulin sensitivity and with the acute 
insulin response to glucose [7].  
 The HR profile during exercise and recovery, which may be modulated by an impaired ability to 
increase vago-sympathetic activity rapidly, is a predictor of sudden death in those without clinically 
detectable cardiovascular disease [8]. Fasting plasma glucose, even at non-diabetic levels, is strongly 
associated with abnormal HR recovery after exercise [6].  
In diabetic patients, a lower HR variability (HRV) has been recognized as an early hallmark of 
CAN, and it predicts mortality [5,9,10]. In asymptomatic diabetic individuals, HRV is a predictor of major 
cardiac events and of silent myocardial ischemia [11]. CAN may impair prognosis through silent coronary 
disease [9], respiratory function, impaired ability to recognise hypoglycaemia, impaired recovery from 
hypoglycaemic episodes, hypertension [12], nephropathy [9], and changes in ventricular repolarization [13].  
In type 2 diabetes, CAN is associated with age, obesity, systolic blood pressure, glycaemic 
control, and duration of diabetes [14] and in non-diabetic individuals, with age, overweight, pre-diabetes, 
HR, diminished HRV, treatment for hypertension, metabolic syndrome and insulin resistance [3,15]. 
Published data do not identify the temporal sequence between autonomic impairment and insulin 
resistance, and autonomic dysfunction could influence glucose dysregulation. Both insulin resistance and 
autonomic dysfunction might have shared precursors, such as physical inactivity or obesity. Interestingly, 
a longitudinal study has shown that autonomic nervous system dysfunction (high HR, low HRV), may be 
associated with incident diabetes [1].  
We hypothesized that HR and HRV may be influenced by long-term glycaemic status per se, 
independently of confounding factors cross-correlated with glycaemic status, HR and HRV. We examined 
the influence of glucose status over the previous nine years, on HR and HRV measured during a 
standardized testing procedure – during rest, deep-breathing, recovery, rest and lying-to-standing. The 
secondary aims were to study the relations of HR and HRV with fasting insulin, the HOMA insulin 
resistance index and the metabolic syndrome, and to see whether a simple forced breathing test is 
adequate to detect reduced parasympathetic activity. 
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Methods 
Participants 
Men and women, aged 30-65 years, consultants in French Social Security health examination centers, 
were recruited in 1994-1996 into the study: Data from an Epidemiological Study on the insulin Resistance 
syndrome (D.E.S.I.R.) [16]; they were invited to health examinations three, six and nine years after 
inclusion. After the year-9 examination, all 321 individuals who had been treated for diabetes or who had 
fasting plasma glucose (FPG) ≥ 7.0 mmol/l at some time during the study, were invited to a year-10 
examination on micro-vascular complications of diabetes; 237 agreed to participate, 17 had died. Control 
groups were also invited: diabetic individuals were matched by age, sex and examination centre to 
individuals with (1) impaired fasting glucose (IFG) at any time during the study (FPG 6.1-6.9 mmol/l) and 
(2) normal glucose levels (FPG < 6.1 mmol/l) during the entire study. The D.E.S.I.R. study was approved by 
the ethics committee of Kremlin Bicêtre Hospital, and participants signed an informed consent.  
All people included in this analysis were free of cardiac disease (22 individuals excluded), and 
respiratory disease (24) and they were not taking medications which could change heart rate: 
neuroleptics (4 individuals excluded), anti-ischemics (29), anti-arrythmics (43), cardiotonics and cardiac 
analeptics (1), thyroid hormone therapy (27), anti-histaminics (8), anti-glaucoma betablockers (1), tricyclic 
anti-depressant (0) or anti-hypertensive treatment other than diuretics, ACE inhibitors and angiotensin-2 
receptor antagonists (108). 
We have defined four glucose status groups:    
1. known diabetic patient – treated by drugs for diabetes at some time during the study, n=70; 
2. screened as diabetic - FPG ≥ 7.0 mmol/l at least once over the 9 years of the study, n=55; 
3. intermediate, impaired fasting glucose – at least one FPG between 6.1 and 6.9 mmol/l, but not known 
as diabetic, n=157; 
4. normal glucose levels during the preceding 9 years of the study - FPG always < 6.1 mmol/l, n=165. 
 
Clinical assessment at baseline and year-10  
Blood pressure was measured with a sphygmomanometer, in a supine position, after 5 minutes of rest and 
one minute after standing. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic 
blood pressure ≥ 90 mmHg or taking antihypertensive medications. Waist circumference (smallest 
circumference between lower rib and iliac crests), weight and height were measured in lightly clad 
participants, and the BMI was calculated.  
Participants completed a self-questionnaire, detailing smoking habits, habitual alcohol intake, and 
drug treatment.  
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Biological measurements at year-10  
HbA1c was measured on a DCA 2000 (Bayer, Puteaux, France) and capillary blood glucose on a glucometer 
(Bayer Diagnostics, Ascensia Glucodisc) just before the autonomic tests.  
 
Biological measurements at baseline and year-9  
At baseline and year-9, biology was from one of four health centre laboratories at La Riche, Blois, 
Chartres or Orleans. Fasting plasma glucose, was measured by the glucose-oxidase method, using a 
Technicon RA100 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta (Konelab, Evry, France). 
HbA1c was measured using an automated HPLC ion-exchange analyser from Hitachi/Merck-VWR or a DCA 
2000 automated immunoassay system from Bayer Diagnostics, Puteaux, France. To adjust for differences 
between laboratories, both glucose and HbA1c data were standardized by age and sex with respect to 
reference data assayed in the La Riche laboratory. Serum insulin was quantified by Micro particle Enzyme 
Immunoassay with an IMX automated analyser from Abbott (Rungis, France). Total cholesterol, HDL-
cholesterol and triglycerides were assayed by a DAX 24 (Bayer Diagnostics, Puteaux, France) or a KONE 
(Evry, France); HOMA insulin-resistance index (HOMA-IR) was calculated, and the AHA/NLBI definition 
of the metabolic syndrome used [17]. 
 
Heart rate and Heart Rate Variability assessment 
HR and HRV have been measured during static conditions (at rest) and dynamic conditions (deep-
breathing and lying-to-standing:  
 5 minutes resting in recumbent position, 
 1 minute deep-breathing in recumbent position: 6 deep respiratory cycles during 1 minute [14], 
 1 minute recovery, 
 1 minute resting,  
 during a lying-to-standing test: participants were asked to stand up quickly [14].  
A 12 derivation ECG was registered at 25 mm/s on a CardioPlug Cardionics ECG Computer Systems 
(Brussels, Belgium) with a program specifically written for this study to time precisely the tests. ECG 
recordings have been edited on a beat-to-beat basis to ensure accurate detection of QRS complexes and 
identification and labeling of premature beats. Mean RR interval, SDNN (standard deviation of normal R-
R intervals (NN) in ms), RMSSD (root mean square of differences between successive R-R intervals 
in ms), PNN50 (percent normal R-R intervals > 50 ms different from previous interval), RR max/RR min, 
(RR max – RR min), were calculated according to consensus guidelines [18], and the RR standardized 
SDNN: SDNN/NN [19]. 
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Statistical Methods 
SAS (version 9.1.3, SAS Institute, Cary, NC). was used for analyses 
Descriptive data are shown as means (standard deviations) or number of participants 
(percentages). HR across glucose groups are shown graphically and compared by analysis of covariance, 
with adjustments for age, sex and additionally for BMI, as well as linear trend tests across groups. HRV 
parameters are shown graphically according to glucose groups, and compared by analysis of covariance 
after appropriate transformation – log(y), -1/y², √y, 1/√y, following inspection of residuals from linear 
models; PNN50 was used as a binary variable (<3rd quartile, ≥3rd quartile), and analyzed by logistic 
regression; strictly normal individuals and the group (IFG and detected diabetic individuals) were also 
compared. Spearman partial correlation coefficients, adjusted on age and sex, were determined between 
HR, HRV (SDNN/NN) and cardio-metabolic risk factors; additional adjustment was made for BMI. 
Relations between HRV (SDNN/NN) at different periods and change in HR between recovery and deep-
breathing were quantified by Spearman correlation coefficients, before and after adjusting on age, sex 
and BMI. 
 
Results 
Characteristics of population studied 
There were 70 patients with known diabetes, mean diabetes duration: 6.4 years; they were well 
controlled: mean HbA1c 6.7% (Table 1). BMI, HbA1c and capillary glucose varied over glucose groups; 
systolic blood pressure and pulse pressure differed significantly, but there was no difference in blood 
pressure changes between lying-to-standing. More known and detected diabetic individuals smoked. Known 
diabetic participants had a more severe cardio-vascular risk profile: 75% had the metabolic syndrome in 
comparison to only 15% in normoglycemic individuals.  
 
Heart rate, heart rate recovery: glycaemic status and factors associated  
HR was related with glycaemic status (Figure 1), particularly during recovery after deep-breathing, and 
during subsequent rest (P < 0.04,0.03), and known diabetic patients had the highest HR. During deep-
breathing in comparison to during rest, mean HR increased less in the known diabetic participants than in 
those always normoglycemic (P < 0.008), a relation attenuated after BMI adjustment (P < 0.1) (Fig. 1, 2A). 
Further, there was a trend across the glycaemic groups (P < 0.01). At recovery after deep-breathing, the 
HR in known diabetic individuals continued to increase, while in all other groups it decreased (Fig. 1, 2B). 
The trend across groups was highly significant (P < 0.009) and remained after BMI adjustment (P < 0.04).  
Capillary glucose, triglycerides and supine blood pressures were positively correlated with HR at 
almost all of testing periods, after age and sex adjustment (Table 2), and these results were little 
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attenuated after additional BMI adjustment. The correlation between blood pressure and HR was 
significant in the normoglycemic subjects, even after BMI adjustment (data not shown). Insulin 
concentrations and the HOMA-IR index correlated positively with HR at some time periods, but these 
correlations disappeared after adjusting on BMI. HR was higher in those with the metabolic syndrome for 
all test periods (Table 2), but was attenuated after adjustment on BMI with a significantly different HR 
remaining only during deep-breathing.  
 
Heart rate variability and glycaemic status  
HRV was more closely related with glycaemic status at deep-breathing and particularly at recovery, than 
at other periods; patients with known diabetes had the lowest HRV (Fig. 3 A-F). At recovery, the 
detected diabetic and IFG individuals had similar HRV, and all six HRV indices were significantly lower 
than in those with normal glucose. After adjustment on BMI the relations were attenuated, and were all 
non significant P < 0.1. 
Age was always associated with HRV, as measured by SDNN/NN, at all test periods. Capillary 
glucose and HbA1c were negatively correlated with SDNN/NN at recovery, after age and sex adjustment, 
(Table 3). BMI, waist circumference, HOMA-IR, triglycerides, HDL-cholesterol and HR were significantly 
correlated with HRV at several time periods, particularly at recovery. (Table 3). Supine blood pressure 
was only related with HRV parameters during lying-to-standing, and this was attenuated but remained 
associated after BMI adjustment. 
In those with the metabolic syndrome, HRV was significantly lower in deep-breathing and recovery 
periods (Table 3), but not after adjustment on BMI.  
The change in HR between recovery and deep-breathing (recovery-[deep-breathing]) was 
correlated with HRV (SDNN/NN), inversely at rest (r= -0.117), positively at deep-breathing (r = 0.210) 
and inversely at recovery (r= -0.326), and these correlations were little changed after adjusting on age, 
sex and BMI. 
 
Discussion 
HR and HRV were assessed during five consecutive periods: rest, deep-breathing, recovery, rest, lying-to-
standing, our results showed:  
1. significant HR difference between the four glycaemic groups; treated diabetic patients had the 
highest HR, those with screened diabetes or IFG had slightly elevated HR in all test periods; HR was 
correlated with capillary glucose and triglycerides during all test periods;  
2. lower increase in HR between rest and deep-breathing in diabetic patients than in others;  
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3. HR which continued to increase between deep-breathing and recovery in diabetic patients in contrast 
to other groups;  
4. differences for HRV according to glycaemic status, especially during deep-breathing and recovery 
periods, attenuated but no longer significant after BMI adjustment; 
5. negative correlation between change in HR between deep-breathing and recovery and HRV at rest, 
and recovery.  
HR was highest in known diabetic patients and slightly higher in dysglycemia (screened diabetes or IFG), 
at all test periods, as seen in other studies [5,6]. HR in non-diabetic individuals, has been found to be 
associated with insulin resistance, with the acute insulin response to glucose and with proinsulin after 
adjustment for demographic characteristics, glucose tolerance status, and smoking [7]. In addition a high 
HR has been shown to predict incident diabetes [1]. Sex, age and BMI may influence HR. In the current 
study the HR during all five periods, correlated significantly with capillary glucose measured at the time 
of examination and with triglycerides even after sex, age and BMI adjustment. HR was slightly faster in 
subjects with metabolic syndrome, significantly during all periods. Higher sympathetic tone can cause 
insulin resistance [20]. Conversely insulin resistance and hyperinsulinemia can cause sympathetic 
overactivity and depress vagal activity in healthy subjects [21] and in insulin-resistant non-diabetic 
offspring of type 2 diabetes patients [22]. In our population, HR correlated with HOMA-IR and fasting 
insulin, but these correlations were no longer significant after BMI adjustment. The present data suggest 
that glucose is a determinant of HR.   
The plasticity of HR to changes provides further information. The heart-rate profile during 
exercise and recovery (high resting HR, low HR increase during exercise, low HR decrease after exercise) 
predicts sudden death [23]. Fasting blood glucose has been reported to be strongly associated with 
abnormal HR recovery after exercise [6]. In our study, in the known diabetic patients, HR increased less 
between rest and deep-breathing and continued to increase during the recovery time after deep-
breathing while in all other groups, HR decreased, the differences remaining significant after BMI 
adjustment. Interestingly, this response in diabetic patients was observed despite the smaller HR 
increase induced by deep-breathing (Fig. 1); individuals detected as diabetic also displayed an abnormal 
response, and there was a significant trend across glycaemic groups. These results suggest that this 
relatively simple test has good sensitivity, and could be a new marker, worthy of evaluation. 
Defects in HR recovery after exercise may result from an impaired ability to increase vagal and 
sympathetic activity rapidly [23]. The mechanism cannot be inferred from our data. However, we found a 
negative correlation between the difference in HR between recovery and deep-breathing and HRV at 
rest, which was modestly attenuated after adjusting on age, sex and BMI. This suggests that alterations 
of the vago-sympathetic balance responsible for abnormal HRV, is involved in the abnormal HR recovery 
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after a minor effort, and that abnormal HR recovery after exercise is a marker of reduced 
parasympathetic activity. 
 Lower HRV has been reported in fasting hyperglycemia [3], glucose intolerance [14]; the metabolic 
syndrome has been implicated in reduced HRV in non-diabetic individuals, independently of glucose [3]. 
Some data suggest that HRV impairment is associated with more severe insulin resistance in non-diabetic 
obese individuals [24]. Obesity is a major contributor to CAN in type 2 diabetic patients [17]. A reduced 
HRV has been reported in 40% of non-diabetic obese patients with a negative correlation between HRV 
during deep-breathing and fasting glycemia [25], but this may be reversed after weight loss [26]. In 
adults with normal fasting glucose, impaired baroreflex sensitivity, another marker of autonomic cardiac 
control, was associated with higher fasting plasma insulin, independent of BMI, physical activity, or blood 
pressure, while there was no multivariable association between fasting glucose and baroreflex sensitivity 
[27]. In our study, using a variety of parameters measuring HRV, we found, in particular during deep-
breathing and recovery, a relation between HRV and glycaemic status; known diabetic patients had the 
lowest HRV. For the SDNN/NN HRV index, which is effectively HR adjusted, there was a large 
difference between the known diabetic patitients and the normoglycaemic during deep-breathing. HRV 
during the five test periods correlated negatively with current capillary blood glucose, BMI, insulin, 
HOMA-IR and triglycerides, and was lower in those with metabolic syndrome; most associations were 
greatly attenuated after adjustment on BMI, which strongly suggests that over-weight may be the 
determinant of HRV and that weight should be included in models when evaluating HRV parameters. 
 
Strength and limitations  
In this study glycaemic status was well defined during the previous nine years, with a three-yearly fasting 
plasma glucose measures. Further HR and HRV were evaluated during five test periods and results were 
often concordant. A limitation of this study is that there was no oral glucose tolerance test – it appears 
that autonomic function is altered in impaired glucose tolerance but not in isolated impaired fasting 
glucose [28]. In our study, some of those with IFG would also have impaired glucose tolerance. Even the 
known diabetic patients in our study were well controlled, whereas HRV abnormalities are usually explored 
in poorly controlled patients.  
 
Clinical implications 
Our results are clinically relevant: elevated HR cardiovascular morbidity and mortality [4], in particular in 
hypertensive patients [29], in diabetic patients [1,2] and in patients with coronary artery disease [30]; 
reduced HRV is predictive of mortality in diabetic patients [5,10]; the HR profile during exercise and 
recovery is associated with sudden death [8,23]. This study extends the clinical utility of HRV in 
overweight and obese people and in individuals with fasting hyperglycemia.  
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In conclusion glycaemic status and glucose are associated with HR but not with HRV, while over-weight 
seems to be associated with HRV. After deep-breathing, HR recovery is altered in known diabetic 
patients, with a trend across glucose groups. HR recovery is associated with reduced HRV in periods 
before and after deep-breathing. Alterations of the vago-sympathetic balance responsible for abnormal 
HRV are involved in abnormal HR recovery after a minor effort such as forced breathing. The value of 
this simple forced deep-breathing test warrants further evaluation in diabetic as well as in pre-diabetic 
patients. 
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Figure Legends 
 
FIGURE 1 Heart rate (beats/minute) according to glucose status across the five test periods; P-values 
for age and sex-adjusted ANOVA and for age and sex-adjusted trend test across the four glucose 
classes at the various test periods. 
 
FIGURE 2 Change in Heart rate (HR) (beats/minute), with SE bars shown, by glycaemic status, between A 
rest period and deep breathing period, B deep breathing period and recovery period; ANOVA and 
trend test comparisons.   
 
FIGURE 3 A – F. Various measures of heart rate variability (HRV) according to glucose status across the 
five test periods; age and sex-adjusted ANCOVA comparison across the 4 glucose classes:  * P < 0.05, 
** P < 0.01, *** P < 0.001; and between normal and (IFG+detected diabetes): + P < 0.05, ++ P < 0.01, +++ 
P < 0.001 
 
12/01/2011 Article 1 15/23 
Table 1 Characteristics (means (standard deviation) or number (percentage)) of participants according to glucose status at examination. The D.E.S.I.R. 
Study 
 
 known diabetic detected diabetic intermediate always normal 
ANOVA   
P-value* 
P trend* 
 n=70 n=55 n=157 n=165  
Measures at the examination       
Age (years) 61 (9) 57 (9) 60 (8) 60 (8)   
Men (%) 48 (69%) 46 (84%) 124 (79%) 127 (77%)   
       
HbA1c (%) 6.7 (1.0) 5.7 (0.5) 5.4 (0.4) 5.2 (0.3) 0.0001 0.0001 
Capillary glycaemia (mmol/l)  ** 8.80 (3.71) 6.37 (1.66) 5.83 (1.16) 5.38 (0.85) 0.0001 0.0001 
Diabetes duration (years) 6.4 (0-35)      
       
BMI (kg/m2) 28.7 (4.5) 26.8 (3.5) 26.9 (3.6) 25.2 (3.4) 0.0001 0.0001 
       
Supine SBP  (mmHg) 142 (20) 138 (16) 139 (17) 134 (18) 0.008 0.002 
Supine DBP (mmHg) 82 (9) 83 (9) 81 (9) 80 (9) 0.3 0.07 
Supine Pulse Pressure (mmHg)** 60 (16) 55 (12) 58 (14) 54 (13) 0.007 0.004 
Lying-to-standing SBP (mmHg) 141 (19) 137 (16) 138 (18) 133 (18) 0.006 0.001 
Lying-to-standing DBP (mmHg) 84 (9) 86 (9) 84 (10) 82 (9) 0.04 0.02 
       
Alcohol (g/day) 16 (15) 21 (26) 20 (16) 17 (17) 0.2 0.7 
Smoker (%)  11 (17%) 10 (20%) 16 (11%) 15 (9%) 0.2 0.04 
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DURING 5 MINUTES AT REST, heart rate and measures of heart rate variability    
Heart rate (beats/minute) 71 (12) 68 (10) 69 (11) 67 (10) 0.07 0.01 
SDNN (ms)** 30.1 (15.6) 35.6 (17.0) 33.4 (15.8) 35.5 (17.8) 0.07 0.02 
RMSSD (ms)** 23.9 (16.2) 22.1 (8.2) 21.9 (13.6) 24.8 (17.3) 0.3 0.4 
PNN50 (%)** 7.22 (11.36) 3.69 (4.09) 4.80 (8.58) 6.14 (10.22) 0.1 0.8 
Max RR / Min RR*** 1.24 (0.12) 1.27 (0.11) 1.28 (0.14) 1.28 (0.13) 0.1 0.08 
Max RR - Min RR** 186 (94) 210 (72) 212 (101) 217 (97) 0.1 0.02 
SDNN/NN** 0.034 (0.014) 0.040(0.02) 0.037 (0.016) 0.039 (0.017) 0.2 0.1 
       
Measures at year 9 of the study       
Supine systolic blood pressure (mmHg) 146 (21) 140 (17) 144 (19) 139 (19) 0.03 0.01 
Supine diastolic blood pressure (mmHg) 84 (10) 84 (9) 84 (11) 82 (10) 0.4 0.2 
Hypertension # 50 (75%) 28 (51%) 98 (62%) 80 (49%) 0.003 0.001 
       
Waist circumference (cm) men 99 (11) 95 (9) 94 (9) 89 (9) 0.0001 0.0001 
Waist circumference (cm) women 92 (10) 89 (14) 88 (12) 79 (8) 0.0002 0.0001 
       
Fasting plasma glucose (mmol/l) ** 8.37 (2.54) 6.6 (1) 5.86 (0.54) 5.12 (0.47) 0.0001 0.0001 
Insulin (pmol/l) ** 104.2 (115.78) 89.66 (52.02) 75.61 (46.28) 51.94 (26.6) 0.0001 0.0001 
HOMA IR ** 5.46 (6.29) 3.76 (2.43) 2.78 (1.77) 1.67 (0.9) 0.0001 0.0001 
Triglycerides (mmol/l) ** 1.65 (1.2) 1.72 (1.24) 1.33 (0.86) 1.14 (0.55) 0.0001 0.0001 
HDL cholesterol (mmol/l) ** 1.33 (0.32) 1.37 (0.3) 1.42 (0.31) 1.51 (0.32) 0.0001 0.0001 
       
Metabolic syndrome (%) 51 (75) 25 (45) 65 (41) 25 (15) 0.0001 0.0001 
* adjusted for age and sex ** log transformation for analysis *** -1/y2 transformation for analysis # Hypertension : systolic /diastolic blood 
pressure ≥ 140/90 mmHg or medication for hypertension 
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Table 2. Spearman partial correlation coefficients, adjusted for age and sex, between heart rate and 
cardio-metabolic risk factors among all participants: at rest, deep breathing, recovery, at rest and lying-to-
standing The mean heart rate (SD) for those with and without the AHA/NHBLI defined metabolic 
syndrome is also given.  
 
 at rest 
deep 
breathing 
recovery at rest 
lying-to-
standing 
Age # 0.010 -0.045 -0.031 -0.024 -0.008 
      
Capillary glucose 0.144** 0.110* 0.140** 0.146** 0.159*** 
HbA1c 0.056 0.023 0.067 0.067 0.057 
      
BMI 0.156*** 0.074 0.118* 0.142** 0.092* 
Waist circumference 0.128** 0.056 0.102* 0.118** 0.107* 
Insulin 0.116** 0.053 0.091 0.100* 0.073 
HOMA-IR 0.143** 0.074 0.120** 0.130** 0.099* 
      
Triglycerides 0.211*** 0.141** 0.193*** 0.209*** 0.129** 
HDL-cholesterol -0.032 0.016 -0.015 -0.029 -0.006 
      
Supine systolic BP  0.177*** 0.214*** 0.171*** 0.165*** -0.089 
Supine diastolic BP 0.165*** 0.191*** 0.161*** 0.150** 0.092* 
      
      
Mean (SD) of Heart Rate (ms) † 
Metabolic syndrome 70 (11) ++ 73 (10) + 73 (11) ++ 71 (11) ++ 79 (12) + 
No Metabolic 
syndrome 
67 (11)  70 (10) 70 (11) 68 (11) 76 (12) 
* P < 0.05, ** P < 0.01, *** P < 0.001 tests are adjusted for age and sex 
† adjusted for age and sex 
# adjusted for sex 
+ P < 0.05, ++ P < 0.01, +++ P < 0.0001: comparisons between individuals with and without the 
metabolic syndrome 
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Table 3. Spearman partial correlation coefficients, adjusted for age and sex between heart rate 
variability parameter, SDNN/NN and cardio-metabolic risk factors among all participants: at rest, deep 
breathing, recovery, at rest and lying-to-standing, and the mean SDNN/NN (SD) for those with and 
without the AHA/NHBLI defined metabolic syndrome.  
 
 at rest 
deep 
breathing 
recovery at rest 
lying-to-
standing 
Age# -0.296*** -0.426*** -0.322*** -0.216*** -0.310*** 
      
Capillary glucose -0.086 -0.084 -0.103* 0.042 -0.006 
HbA1c -0.014 -0.070 -0.094* 0.030 0.004 
      
BMI -0.075 -0.145** -0.224*** -0.040 -0.091* 
Waist circumference -0.059 -0.139** -0.198*** 0.016 -0.082 
Insulin -0.067 -0.085 -0.147** -0.020 -0.077 
HOMA-IR -0.080 -0.099* -0.171*** -0.006 -0.075 
      
Triglycerides -0.078 -0.084 -0.179*** -0.110* -0.033 
HDL-cholesterol 0.035 0.116* 0.101* -0.026 0.058 
      
Systolic BP  -0.030 -0.039 -0.030 0.020 -0.123** 
Diastolic BP -0.008 -0.045 -0.033 -0.000 -0.130** 
Heart rate  -0.176*** -0.046 -0.143** -0.122** -0.111* 
      
      
Mean (SD) SDNN/NN (ms), adjusted on age and sex † 
Metabolic syndrome 0.036 
(0.016) 
0.077 
(0.032)++ 
0.050 
(0.019) + 
0.034 
(0.017) 
0.043  
(0.018) 
No Metabolic 
syndrome 
0.039 
(0.016) 
0.087 
(0.032) 
0.054 
(0.019) 
0.034 
(0.016) 
0.044  
(0.018) 
* P < 0.05, ** P < 0.01, *** P < 0.001 tests are adjusted for age and sex 
+ P < 0.05, ++ P < 0.01: comparisons between individuals with and without metabolic syndrome 
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FIGURE 1. Heart rate (beats/minute) according to glucose status across the five test periods; 
P-values for age and sex-adjusted ANOVA and for age and sex-adjusted trend tests, across 
the four glucose classes at the various test periods. 
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FIGURE 2. Change in heart rate (HR) (beats/minute), with SE bars shown, by glycaemic status, between 
A rest period and deep breathing period, B deep breathing period and recovery period; ANOVA and 
trend test comparisons.   
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FIGURE 3. Various measures of heart rate variability (HRV) according to glucose status across the five 
test periods; age and sex-adjusted ANCOVA comparison across the 4 glucose classes: * P < 0.05, ** P 
< 0.01, *** P < 0.001; between normal and (IFG+detected diabetes): + P < 0.05, ++ P < 0.01, +++ P < 0.001 
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